United States & Regeneron Pharmaceuticals

United States: United States>>> has bolstered precautions, including screening air passengers and suspending visa services, and has provided $13 million in assistance for the response.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

United States: The United States>>> has pledged financial aid and is monitoring the Ebola outbreak, with some of its citizens exposed or infected, but its previous aid cuts and withdrawal from the World Health Organization>>> have been criticized for weakening global health response capacity.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.

United States: The United States>>> is the target market for the biosimilar applications, with the United States — Food and Drug Administration>>> (FDA) being the regulatory authority for approval.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals>>> owns the trademark for Eylea, the reference product for Alvogen>>>'s AVT06 biosimilar. The potential market entry of AVT06 could introduce competition to Regeneron Pharmaceuticals>>>'s product.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals partly funds and supports Atara Biotherapeutics in developing therapies for diseases like inflammatory bowel disease, leveraging the Nobel-winning research.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is expected to announce a deal with the Donald Trump administration after the holidays.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received regulatory approvals for new indications, which is expected to positively impact its revenue and market position.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.